Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Development of an autologous canine cancer vaccine system for resectable malignant tumors in dogs.

Yannelli JR, Wouda R, Masterson TJ, Avdiushko MG, Cohen DA.

Vet Immunol Immunopathol. 2016 Dec;182:95-100. doi: 10.1016/j.vetimm.2016.10.011. Epub 2016 Oct 21.

PMID:
27863558
2.

Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived β-glucans.

Qi C, Cai Y, Gunn L, Ding C, Li B, Kloecker G, Qian K, Vasilakos J, Saijo S, Iwakura Y, Yannelli JR, Yan J.

Blood. 2011 Jun 23;117(25):6825-36. doi: 10.1182/blood-2011-02-339812. Epub 2011 Apr 29.

3.

Pilot study of 1650-G: a simplified cellular vaccine for lung cancer.

Hirschowitz EA, Mullins A, Prajapati D, Baeker T, Kloecker G, Foody T, Damron K, Love C, Yannelli JR.

J Thorac Oncol. 2011 Jan;6(1):169-73. doi: 10.1097/JTO.0b013e3181fb5c22.

4.

Generation and characterization of non-small-cell lung cancer cell lines and clones for use in the study of immunotherapy.

Yannelli JR.

Cancer Biother Radiopharm. 2010 Jun;25(3):269-78. doi: 10.1089/cbr.2010.0766.

PMID:
20578832
5.

Characteristics of PBMC obtained from leukapheresis products and tumor biopsies of patients with non-small cell lung cancer.

Yannelli JR, Tucker JA, Hidalgo G, Perkins S, Kryscio R, Hirschowitz EA.

Oncol Rep. 2009 Dec;22(6):1459-71.

PMID:
19885600
6.

Immunotherapy for lung cancer.

Hirschowitz EA, Yannelli JR.

Proc Am Thorac Soc. 2009 Apr 15;6(2):224-32. doi: 10.1513/pats.200806-048LC. Review.

PMID:
19349492
8.

Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells.

Hirschowitz EA, Foody T, Hidalgo GE, Yannelli JR.

Lung Cancer. 2007 Sep;57(3):365-72. Epub 2007 May 16.

9.

Issues concerning the large scale cryopreservation of peripheral blood mononuclear cells (PBMC) for immunotherapy trials.

Best A, Hidalgo G, Mitchell K, Yannelli JR.

Cryobiology. 2007 Jun;54(3):294-7. Epub 2007 Feb 28.

PMID:
17433284
10.

Vaccines for lung cancer.

Hirschowitz EA, Hiestand DM, Yannelli JR.

J Thorac Oncol. 2006 Jan;1(1):93-104. Review.

11.

The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC).

Yannelli JR, Sturgill J, Foody T, Hirschowitz E.

Lung Cancer. 2005 Mar;47(3):337-50.

PMID:
15713517
12.

On the road to a tumor cell vaccine: 20 years of cellular immunotherapy.

Yannelli JR, Wroblewski JM.

Vaccine. 2004 Nov 15;23(1):97-113. Review.

PMID:
15519713
13.

Growth and functional reactivity of lymphocytes obtained from three anatomic compartments in patients with non-small-cell lung cancer (NSCLC).

Yannelli JR, Hirscowitz E, Wroblewski JM.

Cancer Biother Radiopharm. 2003 Oct;18(5):735-49.

PMID:
14629822
14.

Cell surface phenotyping and cytokine production of Epstein-Barr Virus (EBV)-transformed lymphoblastoid cell lines (LCLs).

Wroblewski JM, Copple A, Batson LP, Landers CD, Yannelli JR.

J Immunol Methods. 2002 Jun 1;264(1-2):19-28.

PMID:
12191505
15.
16.

Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.

Kawakami Y, Dang N, Wang X, Tupesis J, Robbins PF, Wang RF, Wunderlich JR, Yannelli JR, Rosenberg SA.

J Immunother. 2000 Jan;23(1):17-27.

PMID:
10687134
17.

Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.

Foon KA, Lutzky J, Baral RN, Yannelli JR, Hutchins L, Teitelbaum A, Kashala OL, Das R, Garrison J, Reisfeld RA, Bhattacharya-Chatterjee M.

J Clin Oncol. 2000 Jan;18(2):376-84.

PMID:
10637253
18.

Genetic manipulation of primitive leukemic and normal hematopoietic cells using a novel method of adenovirus-mediated gene transfer.

Howard DS, Rizzierri DA, Grimes B, Upchurch D, Phillips GL, Stewart AK, Yannelli JR, Jordan CT.

Leukemia. 1999 Oct;13(10):1608-16.

20.

T cell-receptor V gene use by CD4+ melanoma-reactive clonal and oligoclonal T-cell lines.

Nishimura MI, Custer MC, Schwarz SL, Parker LL, Mixon A, Clay TM, Yannelli JR, Rosenberg SA.

J Immunother. 1998 Sep;21(5):352-62.

PMID:
9789197
21.

Adhesion of tumour-infiltrating lymphocytes to endothelium: a phenotypic and functional analysis.

Adams DH, Yannelli JR, Newman W, Lawley T, Ades E, Rosenberg SA, Shaw S.

Br J Cancer. 1997;75(10):1421-31.

22.

Upregulation of DF3, in association with ICAM-1 and MHC class II by IFN-gamma in short-term human mammary carcinoma cell cultures.

Sgagias MK, Nieroda C, Yannelli JR, Cowan KH, Danforth DN Jr.

Cancer Biother Radiopharm. 1996 Jun;11(3):177-85.

PMID:
10851535
23.

Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience.

Yannelli JR, Hyatt C, McConnell S, Hines K, Jacknin L, Parker L, Sanders M, Rosenberg SA.

Int J Cancer. 1996 Feb 8;65(4):413-21.

24.

Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.

Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA.

J Natl Cancer Inst. 1996 Jan 17;88(2):100-8.

25.

Melanoma tumor-infiltrating lymphocytes derived from four distinct anatomic sites obtained from a single patient: comparison of functional reactivity and melanoma antigen recognition.

Yannelli JR, McConnell S, Parker L, Nishimura M, Robbins P, Yang J, el Gamil M, Kawakami Y.

J Immunother Emphasis Tumor Immunol. 1995 Nov;18(4):263-71.

PMID:
8680654
26.

Human Mig chemokine: biochemical and functional characterization.

Liao F, Rabin RL, Yannelli JR, Koniaris LG, Vanguri P, Farber JM.

J Exp Med. 1995 Nov 1;182(5):1301-14.

27.

Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes.

Kang X, Kawakami Y, el-Gamil M, Wang R, Sakaguchi K, Yannelli JR, Appella E, Rosenberg SA, Robbins PF.

J Immunol. 1995 Aug 1;155(3):1343-8.

PMID:
7543520
28.

Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.

Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yannelli JR, Appella E, et al.

J Immunol. 1995 Mar 1;154(5):2257-65.

PMID:
7868898
29.
30.

Enhanced interleukin-2 production in human tumor-infiltrating lymphocytes engineered by 3'-truncated interleukin-2 gene.

Yamaue H, Kashmiri SV, De Filippi R, Nieroda C, Yannelli JR, Tsang KY, Schlom J.

J Immunother Emphasis Tumor Immunol. 1994 Nov;16(4):262-74.

PMID:
7881635
31.

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.

Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE.

J Natl Cancer Inst. 1994 Aug 3;86(15):1159-66.

PMID:
8028037
32.

T-cell receptor repertoire in tumor-infiltrating lymphocytes. Analysis of melanoma-specific long-term lines.

Nishimura MI, Kawakami Y, Charmley P, O'Neil B, Shilyansky J, Yannelli JR, Rosenberg SA, Hood L.

J Immunother Emphasis Tumor Immunol. 1994 Aug;16(2):85-94.

PMID:
7804531
33.

Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide.

Salgaller ML, Weber JS, Koenig S, Yannelli JR, Rosenberg SA.

Cancer Immunol Immunother. 1994 Aug;39(2):105-16.

PMID:
7519125
34.

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.

Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA.

Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6458-62.

35.

Upregulation of tumor necrosis factor-alpha production by retrovirally transduced human tumor-infiltrating lymphocytes using trans-retinoic acid.

Treisman J, Hwu P, Yannelli JR, Shafer GE, Cowherd R, Samid D, Rosenberg SA.

Cell Immunol. 1994 Jul;156(2):448-57.

PMID:
8025957
36.

In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.

Schwartzentruber DJ, Hom SS, Dadmarz R, White DE, Yannelli JR, Steinberg SM, Rosenberg SA, Topalian SL.

J Clin Oncol. 1994 Jul;12(7):1475-83.

PMID:
8021739
37.

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.

Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA.

J Exp Med. 1994 Jul 1;180(1):347-52.

38.

Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy.

Robbins PF, el-Gamil M, Kawakami Y, Stevens E, Yannelli JR, Rosenberg SA.

Cancer Res. 1994 Jun 15;54(12):3124-6. Erratum in: Cancer Res 1994 Jul 15;54(14):3952.

39.

Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes.

Cole DJ, Taubenberger JK, Pockaj BA, Yannelli JR, Carter C, Carrasquillo J, Leitman S, Steinberg SM, Rosenberg SA, Yang YC.

Cancer Immunol Immunother. 1994 May;38(5):299-303.

PMID:
8162611
40.

T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.

Shilyansky J, Nishimura MI, Yannelli JR, Kawakami Y, Jacknin LS, Charmley P, Rosenberg SA.

Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2829-33.

41.

Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response.

Pockaj BA, Sherry RM, Wei JP, Yannelli JR, Carter CS, Leitman SF, Carasquillo JA, Steinberg SM, Rosenberg SA, Yang JC.

Cancer. 1994 Mar 15;73(6):1731-7.

PMID:
8156501
42.

The development of gene therapy for the treatment of cancer.

Rosenberg SA, Anderson WF, Blaese M, Hwu P, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Ettinghausen SE, et al.

Ann Surg. 1993 Oct;218(4):455-63; discussion 463-4.

43.

T-cell recognition of human melanoma antigens.

Kawakami Y, Nishimura MI, Restifo NP, Topalian SL, O'Neil BH, Shilyansky J, Yannelli JR, Rosenberg SA.

J Immunother Emphasis Tumor Immunol. 1993 Aug;14(2):88-93. Review.

44.

Characterization of human tumor cell lines transduced with the cDNA encoding either tumor necrosis factor alpha (TNF-a) or interleukin-2 (IL-2).

Yannelli JR, Hyatt C, Johnson S, Hwu P, Rosenberg SA.

J Immunol Methods. 1993 May 5;161(1):77-90.

PMID:
8486931
45.

The persistence of human peripheral lymphocytes, tumor infiltrating lymphocytes, and colon adenocarcinomas in immunodeficient mice.

Jicha DL, Yannelli JR, Custer M, Colandrea J, Taubenberger J, Mulé JJ, Rosenberg SA.

J Immunother (1991). 1992 Jan;11(1):19-29.

PMID:
1734945
46.

Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial.

Dillman RO, Oldham RK, Barth NM, Cohen RJ, Minor DR, Birch R, Yannelli JR, Maleckar JR, Sferruzza A, Arnold J, et al.

Cancer. 1991 Jul 1;68(1):1-8.

PMID:
2049729
47.

Enhanced tumor growth of both primary and established human and murine tumor cells in athymic mice after coinjection with Matrigel.

Fridman R, Kibbey MC, Royce LS, Zain M, Sweeney M, Jicha DL, Yannelli JR, Martin GR, Kleinman HK.

J Natl Cancer Inst. 1991 Jun 5;83(11):769-74.

PMID:
1789823
48.

Continuous infusion interleukin-2 and tumor-derived activated cells as treatment of advanced solid tumors: a National Biotherapy Study Group Trial.

Oldham RK, Dillman RO, Yannelli JR, Barth NM, Maleckar JR, Sferruzza A, Cohen RJ, Minor DR, Spitler L, Birch R, et al.

Mol Biother. 1991 Jun;3(2):68-73.

PMID:
1910622
49.

The preparation of effector cells for use in the adoptive cellular immunotherapy of human cancer.

Yannelli JR.

J Immunol Methods. 1991 May 17;139(1):1-16. Review. No abstract available.

PMID:
2040807
50.

Effects of interleukin 4 upon human tumoricidal cells obtained from patients bearing solid tumors.

Jadus MR, Good RW, Crumpacker DB, Yannelli JR.

J Leukoc Biol. 1991 Feb;49(2):139-51.

PMID:
1991997

Supplemental Content

Loading ...
Support Center